TY - JOUR
T1 - Genetically predicted 17β-estradiol and systemic inflammation in women
T2 - A separate-sample Mendelian randomisation analysis in the Guangzhou Biobank cohort study
AU - Zhao, J.
AU - Jiang, C. Q.
AU - Lam, T. H.
AU - Liu, B.
AU - Cheng, K. K.
AU - Kavikondala, S.
AU - Zhang, W. S.
AU - Leung, G. M.
AU - Schooling, C. M.
PY - 2014
Y1 - 2014
N2 - Background: Many chronic diseases are characterised by low-grade systemic inflammation. Oestrogens may promote immune response consistent with sex-specific patterns of diseases. In vitro culture and animal experiments suggest oestrogens are anti-inflammatory and might thereby protect against low-grade systemic inflammation. Evidence from epidemiological studies is limited. Using a Mendelian randomisation analysis with a separate-sample instrumental variable (SSIV) estimator, we examined the association of genetically predicted 17β-estradiol with well-established systemic inflammatory markers (total white cell count, granulocyte and lymphocyte count). Methods: A genetic score predicting 17β-estradiol was developed in 237 young Chinese women (university students) from Hong Kong based on a parsimonious set of genetic polymorphisms (ESR1 (rs2175898) and CYP19A1 (rs1008805)). Multivariable linear regression was used to examine the association of genetically predicted 17β-estradiol with systemic inflammatory markers among 3096 older (50+ years) Chinese women from the Guangzhou Biobank Cohort Study. Results: Predicted 17β-estradiol was negatively associated with white blood cell count (-6.3 103/mL, 95% CI -11.4 to -1.3) and granulocyte count (-4.5 103/mL, 95% CI -8.5 to -0.4) but not lymphocyte count (-1.5 103/mL, 95% CI -3.4 to 0.4) adjusted for age only. Results were similar further adjusted for education, smoking, use of alcohol, physical activity, Body Mass Index, waist-hip ratio, age of menarche, age at menopause, use of hormonal contraceptives and hormone replacement therapy. Conclusions: Endogenous genetically predicted 17β-estradiol reduced low-grade systemic inflammatory markers (white blood cell count and granulocyte count), consistent with experimental and ecological evidence of 17β-estradiol promoting immune response. Replication in a larger sample is required.
AB - Background: Many chronic diseases are characterised by low-grade systemic inflammation. Oestrogens may promote immune response consistent with sex-specific patterns of diseases. In vitro culture and animal experiments suggest oestrogens are anti-inflammatory and might thereby protect against low-grade systemic inflammation. Evidence from epidemiological studies is limited. Using a Mendelian randomisation analysis with a separate-sample instrumental variable (SSIV) estimator, we examined the association of genetically predicted 17β-estradiol with well-established systemic inflammatory markers (total white cell count, granulocyte and lymphocyte count). Methods: A genetic score predicting 17β-estradiol was developed in 237 young Chinese women (university students) from Hong Kong based on a parsimonious set of genetic polymorphisms (ESR1 (rs2175898) and CYP19A1 (rs1008805)). Multivariable linear regression was used to examine the association of genetically predicted 17β-estradiol with systemic inflammatory markers among 3096 older (50+ years) Chinese women from the Guangzhou Biobank Cohort Study. Results: Predicted 17β-estradiol was negatively associated with white blood cell count (-6.3 103/mL, 95% CI -11.4 to -1.3) and granulocyte count (-4.5 103/mL, 95% CI -8.5 to -0.4) but not lymphocyte count (-1.5 103/mL, 95% CI -3.4 to 0.4) adjusted for age only. Results were similar further adjusted for education, smoking, use of alcohol, physical activity, Body Mass Index, waist-hip ratio, age of menarche, age at menopause, use of hormonal contraceptives and hormone replacement therapy. Conclusions: Endogenous genetically predicted 17β-estradiol reduced low-grade systemic inflammatory markers (white blood cell count and granulocyte count), consistent with experimental and ecological evidence of 17β-estradiol promoting immune response. Replication in a larger sample is required.
UR - http://www.scopus.com/inward/record.url?scp=84904185092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904185092&partnerID=8YFLogxK
U2 - 10.1136/jech-2013-203451
DO - 10.1136/jech-2013-203451
M3 - Article
C2 - 24737458
AN - SCOPUS:84904185092
SN - 0143-005X
VL - 68
SP - 780
EP - 785
JO - Journal of Epidemiology and Community Health
JF - Journal of Epidemiology and Community Health
IS - 8
ER -